 "Indoco Remedies gets USFDA nod for blood thinning drug Apixaban tablets")
Drug firm Indoco Remedies on Monday said it has received approval from the US health regulator for blood thinning drug Apixaban tablets.
The approved product is therapeutically equivalent to the reference listed drug Eliquis of Bristol-Myers Squibb.
In a regulatory filing, Indoco Remedies said it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Apixaban tablets in the strengths of 2.5 mg and 5 mg.
Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
Quoting IMS June 2020 moving annual total data, Indoco Remedies said the US market size of Apixaban tablets is USD 11,037 million.
Shares of Indoco Remedies were trading 3.50 per cent higher at Rs 228.95 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app